Related references
Note: Only part of the references are listed.The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data
Gabriel Chodick et al.
CLINICAL INFECTIOUS DISEASES (2022)
COVID-19 Vaccine Makers Plan for Annual Boosters, but It's Not Clear They'll Be Needed
Rita Rubin
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
Sara Y. Tartof et al.
LANCET (2021)
Booster shots for COVID-19—the debate continues
Talha Burki
LANCET INFECTIOUS DISEASES (2021)
Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK
Koen B. Pouwels et al.
NATURE MEDICINE (2021)
Waning Immunity after the BNT162b2 Vaccine in Israel
Yair Goldberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
Noa Dagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection: test negative design study
Ariel Israel et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study
Eleftheria Vasileiou et al.
LANCET (2021)
Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data
Eric J. Haas et al.
LANCET (2021)
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
Victoria Jane Hall et al.
LANCET (2021)
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study
Jamie Lopez Bernal et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
Considerations in boosting COVID-19 vaccine immune responses
Philip R. Krause et al.
LANCET (2021)
SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness
Aziz Sheikh et al.
LANCET (2021)
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
Mark G. Thompson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
H. M. El Sahly et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
S. J. Thomas et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants
Amarendra Pegu et al.
SCIENCE (2021)
Covid-19 vaccination: evidence of waning immunity is overstated
Jake Scott et al.
BMJ-BRITISH MEDICAL JOURNAL (2021)
New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status — New York, May 3–July 25, 2021
Eli S. Rosenberg et al.
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
Gabriel Chodick et al.
JAMA NETWORK OPEN (2021)
Risk of SARS-CoV-2 infection and subsequent hospital admission and death at different time intervals since first dose of COVID-19 vaccine administration, Italy, 27 December 2020 to mid-April 2021
Alberto Mateo-Urdiales et al.
EUROSURVEILLANCE (2020)